Influence of tumor necrosis factor-alpha promoter single nucleotide polymorphisms on clinical response to tumor necrosis factor blocker treatment in patients with rheumatoid arthritis from Guangdong Han population

谢宝钊,黄建林,王明霞,朱尚玲,曹双燕,魏秋静,古洁若
2011-01-01
Abstract:AIM To investigate the influence of single nucleotide polymorphisms(SNPs) in tumor necrosis factor alpha(TNF-α) promoter on clinical responses to TNF blocker treatment in patients with rheumatoid arthritis(RA) from Guangdong Han population.METHODS One hundred health volunteers were used as control group.Fifty-four active RA patients refractory to methotrexate(MTX) treatment were included in this study.Twenty-four of them received 3 infusions of infliximab(3 mg?kg~(-1)) at wk 0,wk 2,and wk 6,and 30 of them received adalimumab 40 or 80 mg subcutaneously every other week for 12 wk treatment.All patients continued to take stable background dose of MTX.Patient' s clinical and laboratory parameters were assessed before and after the treatment at wk 10 for infliximab sub-group or at wk 12 for adalimumab sub-group.Disease activity of patient was assessed by the 28-joint Disease Activity Score(DAS28),and the primary efficacy index is the reduction of DAS28.SNPs were genotyped within tumor necrosis factor-lymphotoxin-alpha(TNF-LTA ) promoter about 1 300 bp.The influence of SNPs in TNF-αpromoter on clinical responses to TNF blocker treatment in patients with RA were analysed.RESULTS Compared with normal controls,the frequency of -857T allele were significantly higher in RA patients(P<0.05),while the genotype frequency distribution of rs 1799964(-1031 C/T) and rs 1800630(-863A/C) in RA patients did not differ from that in normal controls. The RA patients who were -857T allele carriers(genotypes T/T + C/T) got greater reduction on the DAS28 after TNF blocker treatment than the RA patients who were -857C allele carriers(genotypes C/C).COCLUSION The SNPs of rs 1799724(-857C/T) may be one of the susceptibility genotype of RA in Guangdong Han population.RA patients with the T allele of -857C/T SNP respond better to TNF blocker treatment than homozygotes with the C allele.
What problem does this paper attempt to address?